The U.S. Food and Drug Administration today approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.
More:
Transcept receives FDA approval for Intermezzo to treat insomnia
As soldiers return home from tours in Afghanistan and Iraq, America must cope with the toll that war takes on mental health. But the treatment of Post Traumatic Stress Disorder (PTSD) is becoming increasingly expensive, and promises to escalate as yet another generation of veterans tries to heal its psychological wounds.
Visit link:
Quick injection of cortisone can prevent PTSD
Adcetris (brentuximab vedotin), recently FDA approved for Hodgkin lymphoma and systemic anaplastic large cell lymphoma, may cost over $100,000 for a course of treatment, or $4,500 per vial. According to marketers and manufacturers, Seattle Genetics, patients typically need three vials in one dose, and from seven to nine doses per course of treatment – a cost range of from $94,500 to $121,500…
View original post here:
Adcetris May Cost $4,500 Per Vial, Or Over $100,000 For A Course Of Lymphoma Treatment
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that clinical data from four separate clinical studies of EYLEA™ (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts…
Go here to see the original:
Regeneron Announces Clinical Presentations At ASRS 2011 Annual Meeting
Scientists at The Scripps Research Institute have devised a much easier technique for performing a chemical modification used widely in the synthesis of drugs and other products.
Go here to read the rest:
Easier, Cheaper Way Discovered To Make A Sought-After Chemical Modification To Drugs
Relievant Medsystems, Inc. announced the company has received Food and Drug Administration approval of an Investigational Device Exemption (IDE) to begin their SMART pivotal trial to evaluate the safety and effectiveness of the Intracept® System for treatment of chronic low back pain…
Go here to read the rest:
Relievant Medsystems Receives FDA Approval To Begin Pivotal Study To Evaluate The Intracept System For Minimally Invasive Treatment Of Low Back Pain
Lexicon Pharmaceuticals, Inc.
Citeline, an Informa business unit, and the world’s leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer’s Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers an…
Original post:
Global Standardization For Alzheimer’s Biomarkers Moves A Major Step Closer To Reality
Pharma IQ is pioneering new compound management discussion platform with launch of the first ever compound management event – Compound Management and Integrity Online event, which will take an innovative form of 11 online sessions over the course of 5 weeks, beginning 31st of October 2011…
Read more:
Compound Management And Integrity – 11 Online Sessions Over 5 Weeks, From 31st Of October 2011